Pfizer (PFE, $42.21) vaccine gets FDA optimism before emergency approval meeting
Pfizer and BioNTech's jointly developed coronavirus vaccine could be effective after just one dose, the U.S. Food & Drug Administration said Tuesday in its first report. The report comes ahead of its Thursday assessment of the Emergency Use Authorization (EUA) request filed by Pfizer last month.
According to the FDA, individuals infected with COVID 19 could benefit from the Pfizer vaccine. The FDA noted that the vaccine's efficacy after one dose, but before the second dose, was around 52%; its efficacy for trial participants over the age of 55 was 94% after both doses. .It has not noted any specific concerns from the late-stage trials.
Last month, Pfizer said that the vaccine, called BNT162b2, had a 95% efficacy rate across all age and race demographics. The pharmaceutical company said it would be ready to distribute the vaccine 'within hours' of approval by the FDA.
The Centers for Disease Control would take the final decision on allocation at the state and national level.
PFE in upward trend: 10-day moving average broke above 50-day moving average on November 12, 2025
The 10-day moving average for PFE crossed bullishly above the 50-day moving average on November 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on December 01, 2025. You may want to consider a long position or call options on PFE as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on November 06, 2025. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
PFE moved above its 50-day moving average on November 21, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on November 14, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on November 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on November 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.548) is normal, around the industry mean (8.918). P/E Ratio (14.692) is within average values for comparable stocks, (23.843). PFE's Projected Growth (PEG Ratio) (13.900) is very high in comparison to the industry average of (2.042). PFE's Dividend Yield (0.068) is considerably higher than the industry average of (0.026). P/S Ratio (2.297) is also within normal values, averaging (3.625).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement